Compare iShares MSCI Indonesia ETF (EIDO) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Johnson & Johnson — how do they compare? iShares MSCI Indonesia ETF trades at $11.91 (market cap $409.22M), while Johnson & Johnson trades at $261.07 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 1510.4× iShares MSCI Indonesia ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while iShares MSCI Indonesia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Johnson & Johnson for 129 Days on average.
| EIDO | JNJ | |
|---|---|---|
Market Cap | $409.22M | $618.09B |
Volume | 879,527 | 6,050,983 |
52-Week High | $19.22 | $278.43 |
52-Week Low | $10.80 | $186.00 |
Typical Hold Time | 76 Days | 129 Days |
Sector | — | Health |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $11.87, showing minimal daily movement with a 0.08% gain. Technical indicators signal a bearish trend, with moving averages and ADX pointing downward, though RSI levels hint at potential oversold conditions. Recent news highlights underperformance amid sector rotation away from Asian equities, with volume declining 21% below average. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook remains cautious due to weak price action and bearish technicals. Risks include high financials exposure and slow EPS growth. Upside may depend on seasonal trends or valuation support, but current sentiment and institutional flows suggest continued pressure. Investors should weigh technical weakness against potential bargain opportunities.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
